Brightside Health vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 36)
Brightside Health logo

Brightside Health

EmergingHealthTech

Virtual Mental Health

Brightside Health provides virtual mental health treatment for anxiety and depression through a combined therapy, psychiatry, and medication management platform with insurance billing.

AI VisibilityBeta
Overall Score
D36
Category Rank
#525 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
31
Perplexity
32
Gemini
40

About

Brightside Health offers a fully virtual mental health platform that combines licensed therapist sessions, psychiatrist-prescribed medication management, and between-session digital support tools for adults with anxiety and depression. Unlike teletherapy-only platforms, Brightside's integrated care model allows therapists and prescribers on the same platform to coordinate treatment — particularly important for patients with moderate-to-severe symptoms who benefit from both therapy and pharmacotherapy.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

36
Overall Score
81
#525
Category Rank
#17
78
AI Consensus
71
stable
Trend
stable
31
ChatGPT
80
32
Perplexity
75
40
Gemini
77
34
Claude
86
36
Grok
85

Key Details

Category
Virtual Mental Health
General
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Brightside Health
Virtual Mental Health

Integrations

Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.